LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today ...
The diagnostics advisory committee considered evidence on Deep Ensemble for Recognition of Malignancy (DERM) to assess and triage skin lesions referred to the urgent suspected skin cancer pathway from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback